A consensus on the utility of the anti-müllerian hormone assay in the assessment of ovarian reserve and gynecological conditions among Indian gynecologists

Rishma D. Pai; Hrishikesh D. Pai; Nandita Palshetkar; Rakhi Singh; Anju Soni; Ashish Kale; Priti Kumar; Lila Vyas; Mitra Saxena; Surekha Tayade; Gautham Pranesh; Sohini Sengupta

doi:10.18203/2320-1770.ijrcog20243974

Authors

Rishma D. Pai Department of Fertility, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India; Department of Fertility, Hinduja Hospitals, Mumbai, Maharashtra, India
Hrishikesh D. Pai Department of Gynaecology and IVF, Bloom IVF, Mumbai, Maharashtra, India
Nandita Palshetkar Department of Fertility, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India; Department of Fertility, Bloom IVF, Mumbai, Maharashtra, India
Rakhi Singh Department of Fertility, Abalone Clinic & IVF Center, Noida, Uttar Pradesh, India
Anju Soni Department of Gynaecology and Obstetrics, Soni Group of Hospitals, Jaipur, Rajasthan, India
Ashish Kale Department of Fertility, Asha Fertility Centre, Pune, Maharashtra, India; Department of Fertility, Ashakiran Hospital, Pune, Maharashtra, India
Priti Kumar Department of Gynaecology, Narayana Institute of Medical Science, Lucknow, Uttar Pradesh, India
Lila Vyas Department of Gynaecology, Cocoon Hospital, Jaipur, Rajasthan, India
Mitra Saxena Department of Gynaecology and IVF, Shri Ashwini Saxena Hospital, Rewri, Haryana, India
Surekha Tayade Department of Gynaecology, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India
Gautham Pranesh Department of Clinical Development and Research, Mitopower Inc, Bangalore, Karnataka, India
Sohini Sengupta Department of Clinical Biochemistry and Special Assays, Redcliffe Labs, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20243974

Keywords:

Anti-Müllerian hormone, Infertility, Consensus

Abstract

Infertility is a global issue that causes distress. Serum anti-Müllerian hormone (AMH) and antral follicle count are reliable ovarian reserve markers. The stability of serum AMH levels throughout the menstrual cycle makes monitoring ovarian function decline convenient. This consensus aimed to develop recommendations for the application of the AMH assay in assessing ovarian reserve and broader clinical decision-making among gynecologists in India. A modified Delphi method was used, with a panel of 10 expert gynecologists and 2 lab experts from India, to establish an expert consensus. A questionnaire consisting of 29 consensus statements was administered, covering topics related to ovarian reserve, AMH markers, assay reliability, performance, and specific conditions such as ovarian tumors and endometriosis. Through two rounds of the modified Delphi method, 21 consensus statements were ultimately formulated. The consensus was determined using an 80% cutoff. The panel reached a consensus on 19 statements and a moderate consensus on two, emphasizing the significance of AMH testing in evaluating ovarian reserve and reproductive aging. The panel agreed that AMH assays were valuable in predicting ovarian response to fertility treatments, diagnosing polycystic ovary syndrome and endometriosis, and guiding fertility preservation. It was concluded that AMH testing is crucial for infertility management in India, offering insights into ovarian reserve and reproductive aging. Standardized automated assays ensure speed and precision, aiding in diagnosing fertility conditions, predicting treatment responses, and preserving fertility during therapy. International standards for accurate interpretation are imperative. Overall, AMH testing plays a pivotal role in personalized fertility care in India.

Metrics

Metrics Loading ...

References

Mascarenhas MN, Cheung H, Mathers CD, Stevens GA. Measuring infertility in populations: constructing a standard definition for use with demographic and reproductive health surveys. Popul Health Metr. 2012;10:17.

https://doi.org/10.1186/1478-7954-10-17

Purkayastha N, Sharma H. Prevalence and potential determinants of primary infertility in India: Evidence from Indian demographic health survey. Clin Epidemiol Glob Health. 2021;9:162-70.

https://doi.org/10.1016/j.cegh.2020.08.008

World Health Organization. 1 in 6 people globally affected by infertility. 2023. Available at: https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility. Accessed on 22 May 2023.

Priyadarshi S, Tanwar R, Malhotra V, Vinod KV, Krishnappa P, Ali I, et al. The Urological Society of India guidelines for the management of male infertility (Executive Summary). Indian J Urol. 2023;39:7.

https://doi.org/10.4103/iju.iju_243_22

Romanski PA, Brady PC, Farland LV, Thomas AM, Hornstein MD. The effect of endometriosis on the antimüllerian hormone level in the infertile population. J Assist Reprod Genet. 2019;36:1179-84.

https://doi.org/10.1007/s10815-019-01450-9

Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev. 2018;2018:CD012693.

https://doi.org/10.1002/14651858.CD012693.pub2

Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020;105:3361-73.

https://doi.org/10.1210/clinem/dgaa513

Lambert-Messerlian G, Plante B, Eklund EE, Raker C, Moore RG. Levels of antimüllerian hormone in serum during the normal menstrual cycle. Fertil Steril. 2016;105:208-13.

https://doi.org/10.1016/j.fertnstert.2015.09.033

Biniasch M, Laubender RP, Hund M, Buck K, Geyter CD. Intra- and inter-cycle variability of anti-Müllerian hormone (AMH) levels in healthy women during non-consecutive menstrual cycles: the BICYCLE study. Clin Chem Lab Med. 2022;60:597-605.

https://doi.org/10.1515/cclm-2021-0698

Sinha S, Sharan A, Sinha S. Anti-Mullerian Hormone as a Marker of Ovarian Reserve and Function. Cureus. 2022;14:e29214.

https://doi.org/10.7759/cureus.29214

Grisendi V, Mastellari E, La Marca A. Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification. Front Endocrinol. 2019;10:281.

https://doi.org/10.3389/fendo.2019.00281

Wang X, Jin L, Mao Y dong, Shi JZ, Huang R, Jiang YN, et al. Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation-A Real-World Data Analysis of 89,002 Patients. Front Endocrinol. 2021;12:702061.

https://doi.org/10.3389/fendo.2021.702061

Lee JY, Kim CH, Choe SA, Seo S, Kim SH. Measurement of serum anti-Müllerian hormone by revised Gen II or automated assay: Reproducibility under various blood/serum storage conditions. Clin Exp Reprod Med. 2023;50:107-16.

https://doi.org/10.5653/cerm.2022.05687

Han A, Suh B, Yi G, Lee YJ, Kim SE. Comparison of the Automated Fluorescent Immunoassay System With Roche Elecsys and Beckman Coulter Access 2 Assays for Anti-Müllerian Hormone Measurement. Ann Lab Med. 2022;42:47-53.

https://doi.org/10.3343/alm.2022.42.1.47

Pearson K, Long M, Prasad J, Wu YY, Bonifacio M. Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA. Reprod Biol Endocrinol. 2016;14:8.

https://doi.org/10.1186/s12958-016-0143-3

Nelson SM, Pastuszek E, Kloss G, Malinowska I, Liss J, Lukaszuk A, et al. Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. Fertil Steril. 2015;104:1016-21.

https://doi.org/10.1016/j.fertnstert.2015.06.024

Baker VL, Gracia C, Glassner MJ, Schnell VL, Doody K, Coddington CC, et al. Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation. Fertil Steril. 2018;110:506-13.

https://doi.org/10.1016/j.fertnstert.2018.03.031

Meczekalski B, Czyzyk A, Kunicki M, Podfigurna-Stopa A, Plociennik L, Jakiel G, et al. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. J Endocrinol Invest. 2016;39:1259-65.

https://doi.org/10.1007/s40618-016-0497-6

Penzias A, Azziz R, Bendikson K, Falcone T, Hansen K, Hill M, et al. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114:1151-7.

https://doi.org/10.1016/j.fertnstert.2020.09.134

Li HWR, Robertson DM, Burns C, Ledger WL. Challenges in Measuring AMH in the Clinical Setting. Front Endocrinol. 2021;12:691432.

https://doi.org/10.3389/fendo.2021.691432

Palgamkar J, Jindal D, Sawkar S, Deshmukh SD, Katakdhond MS, Ishwar CP, et al. Anti-mullerian hormone levels in indian women seeking infertility treatment: Are Indian women facing early ovarian senescence? J Hum Reprod Sci. 2021;14:380.

https://doi.org/10.4103/jhrs.jhrs_71_21

Umarsingh S, Adam JK, Krishna SBN. The relationship between anti-Müllerian hormone (AMH) levels and pregnancy outcomes in patients undergoing assisted reproductive techniques (ART). Peer J. 2020;8:e10390.

https://doi.org/10.7717/peerj.10390

Scheffer JAB, Scheffer B, Scheffer R, Florencio F, Grynberg M, Lozano DM. Are age and anti-Müllerian hormone good predictors of ovarian reserve and response in women undergoing IVF? JBRA Assist Reprod. 2018;22:215-20.

https://doi.org/10.5935/1518-0557.20180043

Bhide P, Pundir J, Homburg R, Acharya G. Biomarkers of ovarian reserve in childhood and adolescence: A systematic review. Acta Obstet Gynecol Scand. 2019;98:563-72.

https://doi.org/10.1111/aogs.13574

Gunasheela D, Murali R, Appaneravanda L, Gerstl B, Kumar A, Sengeetha N, et al. Age-specific distribution of serum anti-mullerian hormone and antral follicle count in Indian infertile women. J Hum Reprod Sci. 2021;14:372.

https://doi.org/10.4103/jhrs.jhrs_65_21

Punchoo R, Bhoora S. Variation in the Measurement of Anti-Müllerian Hormone - What Are the Laboratory Issues? Front Endocrinol. 2021;12:719029.

https://doi.org/10.3389/fendo.2021.719029

Demirdjian G, Bord S, Lejeune C, Masica R, Rivière D, Nicouleau L, et al. Performance characteristics of the Access AMH assay for the quantitative determination of anti-Müllerian hormone (AMH) levels on the Access* family of automated immunoassay systems. Clin Biochem. 2016;49:1267-73.

https://doi.org/10.1016/j.clinbiochem.2016.08.005

Anderson RA, Anckaert E, Bosch E, Dewailly D, Dunlop CE, Fehr D, et al. Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril. 2015;103:1074-80.

https://doi.org/10.1016/j.fertnstert.2015.01.004

Bosch E, Labarta E, Zuzuarregui J, Iliodromiti S, Nelson SM. Prediction of ovarian response using the automated Elecsys anti-Müllerian hormone assay in gonadotrophin-releasing hormone antagonist cycles. Reprod Biomed Online. 2023;46:295-301.

https://doi.org/10.1016/j.rbmo.2022.10.012

Kaur J, Mahajan N, Mougin B, Eichenlaub E. Age-dependent decline of anti-Müllerian hormone (AMH) in a large population of Indian fertile women as measured using the automated VIDAS® AMH assay. Fertil Sci Res. 2019;6:120.

https://doi.org/10.4103/fsr.fsr_35_19

Sonigo C, Beau I, Binart N, Grynberg M. Anti-Müllerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications. Clin Med Insights Reprod Health. 2019;13:117955811985475.

https://doi.org/10.1177/1179558119854755

Christ JP, Cedars MI. Current Guidelines for Diagnosing PCOS. Diagnostics. 2023;13:1113.

https://doi.org/10.3390/diagnostics13061113

Sengupta S, Rawat S, Upadhay S, Chaudhary K, Singh B, H M, et al. Establishment of age-specific reference intervals for AMH in Indian women and enhancing its use as a diagnostic marker in PCOS. Int J Reprod Contracept Obstet Gynecol. 2023;12:2649-57.

https://doi.org/10.18203/2320-1770.ijrcog20232715

Butt MS, Saleem J, Aiman S, Zakar R, Sadique I, Fischer F. Serum anti-Müllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. BMC Womens Health. 2022;22:199.

https://doi.org/10.1186/s12905-022-01782-2

de Kat AC, van der Schouw YT, Eijkemans MJC, Broer SL, Verschuren WMM, Broekmans FJM. Can Menopause Prediction Be Improved With Multiple AMH Measurements? Results From the Prospective Doetinchem Cohort Study. J Clin Endocrinol Metab. 2019;104:5024-31.

https://doi.org/10.1210/jc.2018-02607

Finkelstein JS, Lee H, Karlamangla A, Neer RM, Sluss PM, Burnett-Bowie SM, et al. Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. J Clin Endocrinol Metab. 2020;105:e1862-71.

https://doi.org/10.1210/clinem/dgz283

Hopeman MM, Cameron KE, Prewitt M, Barnhart K, Ginsberg JP, Sammel MD, et al. A predictive model for chemotherapy-related diminished ovarian reserve in reproductive-age women. Fertil Steril. 2021;115:431-7.

https://doi.org/10.1016/j.fertnstert.2020.08.003

Pilsgaard F, Grynnerup AG ‐A., Løssl K, Bungum L, Pinborg A. The use of anti‐Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and ‐counseling. Acta Obstet Gynecol Scand. 2018;97:1105-13.

https://doi.org/10.1111/aogs.13334

Anckaert E, Denk B, He Y, Torrance HL, Broekmans F, Hund M. Evaluation of the Elecsys® anti-Müllerian hormone assay for the prediction of hyper-response to controlled ovarian stimulation with a gonadotrophin-releasing hormone antagonist protocol. Eur J Obstet Gynecol Reprod Biol. 2019;236:133-8.

https://doi.org/10.1016/j.ejogrb.2019.02.022

Yılmaz Hanege B, Güler Çekıç S, Ata B. Endometrioma and ovarian reserve: effects of endometriomata per se and its surgical treatment on the ovarian reserve. Facts Views Vis ObGyn. 2019;11:151-7.

Pais AS, Flagothier C, Tebache L, Almeida Santos T, Nisolle M. Impact of Surgical Management of Endometrioma on AMH Levels and Pregnancy Rates: A Review of Recent Literature. J Clin Med. 2021;10:414.

https://doi.org/10.3390/jcm10030414

Sumji S, Bhat A, Rashid A, Wani I, Vasudevan V, Sehar T, et al. Evaluation of the Efficacy and Threshold of Serum Anti-mullerian Hormone (AMH) Levels for Diagnosis and Prediction of Polycystic Ovary Syndrome (PCOS) Among Indian Women. Res Square. 2022;1224353.

https://doi.org/10.21203/rs.3.rs-1224353/v1

Legrand C, Keller L, Collinet P, Barbotin AL, Béhal H, Rubod C, et al. Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts. Reprod Biomed Online. 2021;43:205-14.

https://doi.org/10.1016/j.rbmo.2021.04.020

Shrikhande L, Shrikhande B, Shrikhande A. AMH and Its Clinical Implications. J Obstet Gynecol India. 2020;70:337-41.

https://doi.org/10.1007/s13224-020-01362-0

Gromski PS, Patil RS, Chougule SM, Bhomkar DA, Jirge PR, Nelson SM. Ethnic discordance in serum anti-Müllerian hormone in European and Indian healthy women and Indian infertile women. Reprod Biomed Online. 2022;45:979-86.

https://doi.org/10.1016/j.rbmo.2022.06.023

Pradhan MR, Patel SK, Patel S. Risk Factors and Spatial Clustering of Primary Infertility in India. J Infertil Reprod Biol. 2021;9:27-34.

Mahey R, Gupta M, Kandpal S, Malhotra N, Vanamail P, Singh N, et al. Fertility awareness and knowledge among Indian women attending an infertility clinic: a cross-sectional study. BMC Womens Health. 2018;18:177.

https://doi.org/10.1186/s12905-018-0669-y

Datta A, Chowdhury S, Chowdhury RG, Bhattyacharya B, Chatterjee S. Effect of Female Genital Tubercular Involvement on Anti-Mullerian Hormone Secretion in Latent Genital Tuberculosis Affected Women. Reprod Med Gynecol Obstet. 2019;4:018.

https://doi.org/10.24966/RMGO-2574/100018

Grace GA, Devaleenal DB, Natrajan M. Genital tuberculosis in females. Indian J Med Res. 2017;145:425-36.

https://doi.org/10.4103/ijmr.IJMR_1550_15